SCHEDULE: Soleus Capital Reports 7.5% Stake in Palisade Bio

Soleus Capital Master Fund, L.P. and affiliated entities have disclosed beneficial ownership of 7.5% of Palisade Bio, Inc.'s common stock.

Summary

• Soleus Capital Master Fund, L.P., along with related entities Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy, have filed a Schedule 13G.
• This filing indicates beneficial ownership of 13,063,687 shares of Palisade Bio, Inc. common stock.
• This represents 7.5% of the total outstanding shares.
• The shares are held directly by Soleus Capital Master Fund, L.P.
• The filing clarifies that while these entities share voting and dispositive power, they disclaim beneficial ownership beyond determining their Section 13(d) obligations.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily reporting a change in beneficial ownership without new operational or financial disclosures.

Positives

• Disclosure of a significant ownership stake (7.5%) by Soleus Capital, indicating investor interest in Palisade Bio.

Negatives

• The filing does not contain any new operational or financial performance data for Palisade Bio, Inc.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Palisade Bio, Inc.'s future performance.

Management Comments

• Each of SCG, Soleus Capital, LLC, SCM, Soleus GP and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, as amended (the "Exchange Act"), and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in public companies. This filing indicates Soleus Capital's strategic interest in Palisade Bio, Inc., but does not provide insights into the company's operational performance or future prospects.

Stakeholder Impact

• Shareholders may view the increased institutional interest as a positive sign, potentially leading to greater liquidity or strategic focus on the company.

Key Dates

Keywords

beneficial ownership, Schedule 13G, Palisade Bio, Soleus Capital, common stock, investment management